Loading...
Market
Transcarent announces major acquisition in 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Company press releases, SEC filings, or major news outlets
Story
Transcarent Raises $126M, Valued at $2.2B, Eyes AI Expansion and Acquisitions
May 2, 2024, 03:30 PM
Transcarent, a health tech unicorn co-founded by Glen Tullman, has successfully raised $126 million in a Series D funding round. The round was led by General Catalyst and 7wireVentures. This new influx of capital, which values Transcarent at $2.2 billion, is earmarked for advancing AI projects and strategic acquisitions. The funding signifies a positive shift in the health tech funding landscape, suggesting a market rebound.
View original story
Similar markets
Tech services company • 33%
Software development company • 33%
Other • 34%
Approval • 33%
Conditional Approval • 33%
Rejection • 34%
Bristol Myers Squibb • 25%
Gilead Sciences • 25%
Novartis • 25%
Other • 25%
Media company • 33%
Technology company • 33%
No major acquisition • 34%
